| 000 | 01706 a2200493 4500 | ||
|---|---|---|---|
| 005 | 20250517221756.0 | ||
| 264 | 0 | _c20190514 | |
| 008 | 201905s 0 0 eng d | ||
| 022 | _a1440-1746 | ||
| 024 | 7 |
_a10.1111/jgh.14301 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aGoel, Amit | |
| 245 | 0 | 0 |
_aCost-effectiveness of generic pan-genotypic sofosbuvir/velpatasvir versus genotype-dependent direct-acting antivirals for hepatitis C treatment. _h[electronic resource] |
| 260 |
_bJournal of gastroenterology and hepatology _cDec 2018 |
||
| 300 |
_a2029-2036 p. _bdigital |
||
| 500 | _aPublication Type: Comparative Study; Journal Article | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aAntiviral Agents _xadverse effects |
| 650 | 0 | 4 |
_aCarbamates _xadverse effects |
| 650 | 0 | 4 | _aComputer Simulation |
| 650 | 0 | 4 | _aCost-Benefit Analysis |
| 650 | 0 | 4 | _aDrug Combinations |
| 650 | 0 | 4 | _aDrug Costs |
| 650 | 0 | 4 |
_aDrugs, Generic _xadverse effects |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aGenotype |
| 650 | 0 | 4 |
_aHepacivirus _xdrug effects |
| 650 | 0 | 4 |
_aHepatitis C _xdiagnosis |
| 650 | 0 | 4 |
_aHeterocyclic Compounds, 4 or More Rings _xadverse effects |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aIndia |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aModels, Economic |
| 650 | 0 | 4 | _aQuality of Life |
| 650 | 0 | 4 | _aQuality-Adjusted Life Years |
| 650 | 0 | 4 |
_aSofosbuvir _xadverse effects |
| 650 | 0 | 4 | _aTime Factors |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aChen, Qiushi | |
| 700 | 1 | _aChhatwal, Jagpreet | |
| 700 | 1 | _aAggarwal, Rakesh | |
| 773 | 0 |
_tJournal of gastroenterology and hepatology _gvol. 33 _gno. 12 _gp. 2029-2036 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1111/jgh.14301 _zAvailable from publisher's website |
| 999 |
_c28492787 _d28492787 |
||